source
- Genmab shares jump as petosemtamab plus Keytruda halves death risk in head-neck cancer trialGenmab reported that a late-stage study of its experimental antibody petosemtamab combined with Keytruda cut the risk of death by about 50 percent compared with Keytruda alone in patients with PD‑L…
- Labor Dept finalizes PBM disclosure rule to boost transparency for self-insured employersThe U.S. Labor Department has finalized a rule that will require pharmacy benefit managers to disclose detailed fee and compensation information to self-insured employer clients, with the requireme…